1Campbell RK, Campbell LK, White JR. Insulin lispro: its role in the treatment of diabetes mellitus. Ann Pharmacother1996 Nov;30(11): 1263.
2Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin - analyog treatment. Diabetes 1997Feb;46(2) :265.
3Zinman B, Ross S, Campos RV, et al. Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regrimen. A double- blind randomized prospective trial. Diabetes Care 1999Apr;22(4)603.
4Roach P, Trautmann M, Arora V, et al. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during trestment with two novel insulin ispro- protamine formulations, insulin lispro mix25 and insulin lispro mix50. Clin Ther1999 Mar;21(3) :523.
5Basty EJ 3rd, Stuart CA, Brodows RG, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 2000 Sep;23(9):1236.
6Heller SR, Amiel SA, Mansell P. Effect of the fast - acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. Diabetes Care 1999 Oct; 22 ( 10 ):1607.
7Glazer NB, Zalani S, Anderson JH Jr, et al. Safety of insulin lispro:pooled data from clinical trials. Am J Health Syst Pharm1999 Mar 15;56(6):542.
8Jovanovic L, Ilic S, Pettitt DJ, et al. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 1999 Sep;22(9):1422.
